Key result
Coronary microvascular dysfunction drives HFpEF progression, yet targeted therapies remain lacking.
Why the study?
The pathophysiological mechanisms linking coronary microvascular dysfunction to heart failure remain incompletely understood, its diagnosis is challenging, and no specific therapeutic strategy currently targets it.
Coronary microvascular dysfunction is a prevalent and prognostically significant feature across the heart failure spectrum, particularly in HFpEF, yet specific targeted therapies remain an unmet clinical need.
CMD's role in HFpEF progression remains untargeted; leaves open prospective trials to test specific therapies.
Coronary microvascular dysfunction (CMD) plays a crucial role across the spectrum of heart failure (HF) pathology, contributing to disease development, progression, and outcomes. The pathophysiological mechanisms linking CMD to HF are complex and still not completely understood and include chronic inflammation, oxidative stress, and neurohormonal activation. Despite the diagnostic and prognostic relevance in patients with HF, there is no specific therapeutic strategy targeting CMD to date. Moreover, the diagnosis of this clinical condition is challenging. In this review article, we aim to discuss the different clinical pathogenetic mechanisms linking CMD to HF across the different spectra of these diseases, their prognostic relevance, and the possible therapeutic targets along with the remaining knowledge gaps in the field.
No takes yet. Share an insight, caveat, or question.
Vecchia et al. (2024) conducted a review in Heart failure and coronary microvascular dysfunction. Coronary microvascular dysfunction plays a crucial role in the pathogenesis and progression of heart failure, particularly heart failure with preserved ejection fraction, though specific targeted therapies remain lacking.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: